AstraZeneca and Abbott Laboratories have filed their new combination drug Certriad with regulators in the USA for the treatment of mixed dyslipidemia.

Certriad combines AstraZeneca's blockbuster Crestor (rosuvastatin) with TriLipix (fenofibric acid), Abbott’s recently-approved drug which was developed with Solvay. If approved by the US Food and Drug Administration, the combo would treat two or more lipid abnormalities including high LDL- cholesterol (the 'bad' cholesterol), high triglycerides and low HDL-cholesterol (the 'good' type).

Eugene Sun, vice president of global pharmaceutical clinical development at Abbott, said that patients with mixed dyslipidemia represent “an underserved segment” and Certriad could become an important treatment option. More than 100 million adults in the USA have dyslipidemia and 34 million people are affected by mixed dyslipidemia.

AstraZeneca has also signed a deal, the financial details of which were not disclosed, to co-promote TriLipix in the USA. Jim Helm, vice president, cardiovascular, at the firm’s US subsidiary, noted that part of the firm’s “corporate strategy is to establish successful external collaborations”. He added that with clinical data to support its use in helping certain patients with mixed dyslipidemia to manage all three key lipids, “TriLipix is another important therapeutic option we can now offer physicians”.

The deal is an extension of an agreement signed in August last year when Abbott signed up to co-promote Crestor in the USA. Collaborations seem to be the name of the game for AstraZeneca which earlier this week announced a link-up with Merck & Co to develop a novel combination anticancer regimen composed of two investigational compounds.